Abstract
The incidence of cancer is gradually increasing, and at the same time, the proportion of cancer survivors is also increasing. A study from England showed that the overall survival increased and reported a recent 10-year survival rate of about 50% in 2010–2011 [1]. In South Korea, statistics showed that the incidence of cancer was 475.3 per 100,000 individuals in 2018. If people live to life expectancy (83 years in south Korea), the chance of being diagnosed with cancer is 37.4% and the 10-year survival rate was about 67% in 2009–2013 [2]. There were 15.5 million cancer survivors in 2016 and there will be 26.1 million in the United States by 2040 [3]. Cancer survivors are increasing every year, so it is time to pay greater attention to their health problems. In 2005, a publication of the landmark report of cancer survivors, “From Cancer Patients to Cancer Survivor: Lost in Transition” by the Institute of Medicine [4] introduced ten recommendations to strengthen care in the growing population of survivors transitioning to life after treatment (Table 1).
Sung Yong Han is the lead author of this chapter.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Quaresma M, Coleman MP, Rachet B. 40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971–2011: a population-based study. Lancet. 2015;385:1206–18.
Anonymous. National cancer information center. http://www.cancer.go.kr.
Shapiro CL. Cancer survivorship. N Engl J Med. 2018;379:2438–50.
Council NR. From cancer patient to cancer survivor: lost in transition. Washington, DC: National Academies Press; 2005.
Yabroff KR, Lawrence WF, Clauser S, Davis WW, Brown ML. Burden of illness in cancer survivors: findings from a population-based national sample. J Natl Cancer Inst. 2004;96:1322–30.
Bluethmann SM, Mariotto AB, Rowland JH. Anticipating the “silver tsunami”: prevalence trajectories and comorbidity burden among older cancer survivors in the United States. Philadelphia: AACR; 2016.
Hahn EE, Gould MK, Munoz-Plaza CE, Lee JS, Parry C, Shen E. Understanding comorbidity profiles and their effect on treatment and survival in patients with colorectal cancer. J Natl Compr Cancer Netw. 2018;16:23–34.
Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291:2441–7.
Pinkhas D, Ho T, Smith S. Assessment of pazopanib-related hypertension, cardiac dysfunction and identification of clinical risk factors for their development. Cardio-oncology. 2017;3:1–14.
Totzeck M, Mincu R-I, Mrotzek S, Schadendorf D, Rassaf T. Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: a meta-analysis of approximately 29,000 cancer patients. Eur J Prev Cardiol. 2018;25:482–94.
Tonia T, Mettler A, Robert N, Schwarzer G, Seidenfeld J, Weingart O, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. 2012;12(12):CD003407.
Goodwin JE, Geller DS. Glucocorticoid-induced hypertension. Pediatr Nephrol. 2012;27:1059–66.
Xiao Y, Wang H, Tang Y, Yan J, Cao L, Chen Z, et al. Increased risk of diabetes in cancer survivors: a pooled analysis of 13 population-based cohort studies. ESMO Open. 2021;6:100218.
Perez A, Jansen-Chaparro S, Saigi I, Bernal-Lopez MR, Miñambres I, Gomez-Huelgas R. Glucocorticoid-induced hyperglycemia (糖皮质激素诱导的高血糖). J Diabetes. 2014;6:9–20.
Ariaans G, De Jong S, Gietema J, Lefrandt J, de Vries E, Jalving M. Cancer-drug induced insulin resistance: innocent bystander or unusual suspect. Cancer Treat Rev. 2015;41:376–84.
Porporato P. Understanding cachexia as a cancer metabolism syndrome. Oncogenesis. 2016;5:e200.
Zhang F, Wang K, Du P, Yang W, He Y, Li T, et al. Risk of stroke in cancer survivors: a meta-analysis of population-based cohort studies. Neurology. 2021;96:e513–e26.
Chen J, Zhu M, Ma G, Zhao Z, Sun Z. Chlamydia pneumoniae infection and cerebrovascular disease: a systematic review and meta-analysis. BMC Neurol. 2013;13:1–13.
Chiang C-H, Huang C-C, Chan W-L, Chen Y-C, Chen T-J, Lin S-J, et al. Association between mycoplasma pneumonia and increased risk of ischemic stroke: a nationwide study. Stroke. 2011;42:2940–3.
Deniz K, O'Mahony S, Ross G, Purushotham A. Breast cancer in women after treatment for Hodgkin’s disease. Lancet Oncol. 2003;4:207–14.
Shah BK, Khanal A, Hewett Y. Second primary malignancies in adults with gastric cancer—a US population-based study. Front Oncol. 2016;6:82.
Yang J, Terebelo HR, Zonder JA. Secondary primary malignancies in multiple myeloma: an old NEMESIS revisited. Adv Hematol. 2012;2012:801495.
El-Shami K, Oeffinger KC, Erb NL, Willis A, Bretsch JK, Pratt-Chapman ML, et al. American Cancer Society colorectal cancer survivorship care guidelines. CA Cancer J Clin. 2015;65:427–55.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Chun, H.J., Park, S.J., Lim, Y.J., Song, S.Y. (2023). Survivorship Care for Gastrointestinal Cancer. IV-2. Diseases Other Than Cancer. In: Gastrointestinal Cancer. Springer, Singapore. https://doi.org/10.1007/978-981-99-0815-8_75
Download citation
DOI: https://doi.org/10.1007/978-981-99-0815-8_75
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-99-0814-1
Online ISBN: 978-981-99-0815-8
eBook Packages: MedicineMedicine (R0)